EPIROCIN 0.3% price in UAE

Overview

Welcome to Dwaey, specifically on EPIROCIN 0.3% Eye Drops page.
This medicine contains an important and useful components, as it consists of Ciprofloxacin (as HCl).
EPIROCIN 0.3% is available in the market in concentration 3mg/ml and in the form of Eye Drops.

EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES CO. (E.I.P.I.Co.) is the producer of EPIROCIN 0.3% and it is imported from EGYPT, The most popular alternatives of EPIROCIN 0.3% are listed downward .

Mode Of Action

Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.

Indication

Otitis media
Superficial ophthalmic infections
Otitis externa

Precaution

Prolonged use of Ciprofloxacin may result in overgrowth of nonsusceptible organisms including fungi. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. Not for injection into the eye. Lactation: Drug is distributed into milk; use with caution

Side Effects

>10% Burning
Ciprofloxacin precipitate in superficial portion of corneal defect
Stinging 1-10% Conjunctival hyperemia
Crystals or scales on eyelashes
Foreign-body sensation
Itching
Keratopathy or keratitis
Lid margin crusting
Unpleasant taste after instillation <1% Corneal infiltrates
Corneal staining
Decrease in vision
Lid edema
Ocular discomfort
Photophobia
Sensitivity reactions
Tearing

Contra indication

Ciprofloxacin is contraindicated in patients who have hypersensitivity to Ciprofloxacin or other quinolones.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin. Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.